SCHEMBL584764

SCHEMBL584764

Nc1cc(C2CCC3(C2)OCCO3)nc2ccnn12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 11/20 0.53
CDK2 P24941 11/20 0.53
CCNA2 P20248 10/20 0.53
CCNA1 P78396 10/20 0.53
PDE10A Q9Y233 2/20 0.35
TRPV3 Q8NET8 1/20 0.31
IKBKE Q14164 1/20 0.31
TBK1 Q9UHD2 1/20 0.31
CDK9 P50750 5/20 0.31
CDK7 P50613 3/20 0.31
CDK13 Q14004 2/20 0.31
CDK12 Q9NYV4 2/20 0.31
CCNT1 O60563 4/20 0.31
CDK4 P11802 2/20 0.31
CCND1 P24385 2/20 0.31
CCNH P51946 2/20 0.31
CCNK O75909 1/20 0.30
CDK14 O94921 1/20 0.30
CYP1A2 P05177 1/20 0.30
CDK1 P06493 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL584095 0.93 CHEK1 (0.57) CHEK1CDK2CCNA2CCNA1PDE10A
SCHEMBL583997 0.92 CHEK1 (0.55) CHEK1CDK2CCNA2CCNA1PDE10A
SCHEMBL584914 0.85 PDE10A (0.46) CHEK1CDK2CCNA2CCNA1PDE10A
SCHEMBL594485 0.85 CHEK1 (0.37) CHEK1CDK2CCNA2CCNA1PDE10A
SCHEMBL7846641 0.79 CHEK1 (0.68) CHEK1CDK2CCNA2CCNA1PDE10A
SCHEMBL584081 0.78 PDE10A (0.43) CHEK1CDK2CCNA2CCNA1PDE10A
SCHEMBL584609 0.78 TRPV3 (0.42) CHEK1CDK2CCNA2CCNA1PDE10A
SCHEMBL583594 0.77 CHEK1 (0.38) CHEK1CDK2CCNA2CCNA1PDE10A
SCHEMBL584212 0.77 PDE10A (0.48) CHEK1CDK2CCNA2CCNA1PDE10A
SCHEMBL21498 0.75 CDK2 (0.53) CHEK1CDK2CCNA2CCNA1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8591943-B2 Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2013-11-26 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
EP-2417138-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS Schering Corporation (US) 2012-02-15 EP disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 WO disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR CHEK1 461/4885CDK2 165/4885CCNA2 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.